Also Released
mRNA-4157
Moderna/Merck mRNA cancer vaccine clears Phase 3 in melanoma
Moderna and Merck's Phase 3 trial of mRNA-4157, a personalized mRNA cancer vaccine, met both its primary and secondary endpoints in 1,137 patients with advanced melanoma — one of the deadliest cancers and one of the first personalized treatments of its kind headed to market. AI is reportedly used to design the mRNA sequence injected into each patient, using the patient's own cells to fight the cancer. Moderna surged 115% in a day on the news.
1,137 advanced melanoma patients in the Phase 3 trial115% Moderna stock surge in one day